公开(公告)号：WO2004048320B1

公开(公告)日：2004-08-19

申请号：PCT/US0337511

申请日：2003-11-20

申请人： JACOBUS PHARMACEUTICAL COMPANY

发明人： JACOBUS DAVID P ,  SCHIEHSER GUY ALAN ,  SHIEH HONG-MING ,  JENSEN NORMAN P ,  TERPINSKI JACEK

IPC分类号： A61P31/04 ,  C07C279/26 ,  C07C317/22 ,  C07C323/20 ,  C07D251/10 ,  C07D317/64 ,  C07D319/20 ,  A61K31/155 ,  A61K31/53

CPC分类号： C07C317/22 ,  C07C279/26 ,  C07C323/20 ,  C07D251/10 ,  C07D317/64 ,  C07D319/20 ,  Y10T436/147777

摘要： Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.

摘要翻译： 双胍和二氢三嗪衍生物，优选取代的衍生自羟胺的不对称亚氨基二甲酰亚胺二酰胺，以及含有双胍和二氢三吖嗪衍生物的组合物。 此外，公开了使用双胍和二氢三嗪衍生物，特别是作为抗微生物剂的方法以及在生物测定中使用二氢三嗪衍生物的方法。 还公开了制备双胍和二氢三嗪衍生物的方法。

公开(公告)号：WO2008085484A2

公开(公告)日：2008-07-17

申请号：PCT/US2007026350

申请日：2007-12-26

申请人： JACOBUS PHARMACEUTICAL COMPANY ,  JACOBUS DAVID P ,  SCHIEHSER GUY ALAN ,  ALES KATHY LYNNE ,  JACOBUS LAURA RANSOM

发明人： JACOBUS DAVID P ,  SCHIEHSER GUY ALAN ,  ALES KATHY LYNNE ,  JACOBUS LAURA RANSOM

IPC分类号： A61K31/60 ,  A61K9/14 ,  A61P29/00

CPC分类号： A61K31/60 ,  A61K9/0031 ,  A61K9/0095 ,  A61K9/5026

摘要： Methods are disclosed for treating patients suffering from inflammatory bowel disease, including ulcerative colitis or Crohn's disease, by administering an oral or enema dosage form containing at least one aminosalicylate active ingredient. Granular dosage forms and kits are also disclosed.

摘要翻译： 公开了通过施用含有至少一种氨基水杨酸酯活性成分的口服或灌肠剂型治疗患有炎性肠病，包括溃疡性结肠炎或克罗恩病的患者的方法。 还公开了颗粒剂型和试剂盒。

公开(公告)号：WO9707795A3

公开(公告)日：1997-03-27

申请号：PCT/US9614251

申请日：1996-08-23

申请人： JACOBUS PHARMACEUTICAL COMPANY ,  JACOBUS DAVID P ,  JENSEN NORMAN P

发明人： JACOBUS DAVID P ,  JENSEN NORMAN P

IPC分类号： A61K31/17 ,  C07C317/42

CPC分类号： C07C317/42 ,  A61K31/17

摘要： 1-[4-(4'-sulfanilyl)phenyl]urea and its various substituted derivatives can be used to decrease the infectiousness of and reduce the mortality associated with organisms of the genus Leishmania which are responsible for a group of conditions known as Leishmaniasis. This heretofore unrecognized use extends to the known derivatives of ureidodiaminodiphenyl sulfones and includes the novel aryl-ring hydroxylated series of sulfanilylphenylureas of the formula: wherein m and n can be the same or different and may each =0 or 1, R1, R2, R3, R4, R5, and R6 are the same or different and are selected from the group consisting of hydrogen, hydroxyl, halo, C1 to C6 straight or branch chain alkyl, halo alkyl, polyhalo alkyl, alkoxy, cyano, amino, alkanoylamino, alkoxycarbonylamino, carboxy, alkoxycarbonyl, carbamoyl, acyl, R7, and R8 are the same or different and are selected from the group consisting of hydrogen, and C1 to C6 straight or branch chain alkyl Z is amino, acylamino, alkoxycarbonylamino, alkylamino, substituted amino or nitro; or its pharmaceutically acceptable salts.